MZT1通过准NEDD1来保护胃癌免受葡萄糖饥饿的影响
Ruiyang Zhao1, Bo Cao1, Hanghang Li1
1Department of General Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China; Medical School of Chinese PLA, Beijing 100853, China.
一种新型蛋白质MZT1在葡萄糖剥夺期间在胃癌 (GC) 中升高调节,促进对禁食模仿饮食 (FMD) 的抵抗力. 抑制MZT1可以通过克服耐药性和提高口病疗效来增强GC疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 禁食模仿饮食 (FMD) 显示了胃癌 (GC) 的治疗潜力.
- 口热的不耐受性和有限的疗效限制了其临床应用.
- 识别耐药机制对于改善GC疗法至关重要.
研究的目的:
- 确定在GC中介于对葡萄糖饥饿的抵抗的点.
- 探索MZT1在GC中的临床价值和调控功能.
- 研究MZT1作为GC的潜在治疗标.
主要方法:
- 在缺乏葡萄糖的情况下分析蛋白质表达的蛋白质组学分析.
- 在体外和体内实验来评估MZT1在GC细胞中的功能.
- 研究涉及NEDD1无处不在的MZT1机制.
主要成果:
- 在缺乏葡萄糖的情况下,MZT1在GC细胞中显著上调.
- 在GC组织中MZT1水平升高与患者预后不佳相关.
- 下调MZT1抑制了GC的增殖,迁移,入侵和糖解,使细胞对葡萄糖饥饿敏感.
- MZT1通过抑制NEDD1无化并增加其表达来促进GC恶性瘤.
结论:
- 通过抑制NEDD1无处置,MZT1上调促进GC对葡萄糖饥饿的抵抗.
- MZT1是GC的潜在生物标志物和治疗点.
- 抑制MZT1可以提高口病在GC治疗中的有效性.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
相关概念视频
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitogens and the Cell Cycle
Abnormal Proliferation
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
